Paper Details

  1. Home
  2. Paper Details

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Coadministered Ruxolitinib and Artemether-Lumefantrine in Healthy Adults.

Author: AblaNada, BarberBridget E, BarnesKaren I, BoyleMichelle J, ChalonStephan, ChughlayM Farouk, El GaaloulMyriam, EngwerdaChristian R, GriffinPaul, KressAnita, MarquartLouise, McCarthyJames S, MöhrleJörg J, ReuterStephanie E, SchultzHayley B, TapleyPeter, WebsterRebecca A, WellsTimothy, van GiersbergenPaul

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Despite recurrent malaria infection, individuals in endemic areas remain vulnerable to reinfection. This randomized, placebo-controlled phase 1 trial investigated the safety and pharmacokinetics of combining ruxolitinib, a JAK1/2 inhibitor, with artemether-lumefantrine, an antimalarial drug. The combination was well-tolerated, with adverse events and pharmacokinetics consistent with those of individual drugs. Ruxolitinib significantly inhibited pSTAT3 phosphorylation, a key factor in parasite-induced dysfunctional immune responses. This study supports further investigation of this combination for treating malaria infections.
Paper Details　
Original Abstract of the Article :
Despite repeated malaria infection, individuals living in areas where malaria is endemic remain vulnerable to reinfection. The Janus kinase (JAK1/2) inhibitor ruxolitinib could potentially disrupt the parasite-induced dysfunctional immune response when administered with antimalarial therapy. This ra...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765294/

データ提供：米国国立医学図書館（NLM）

Combining Ruxolitinib and Artemether-Lumefantrine: A Potential Treatment for Malaria

Malaria is like a desert heatwave, a deadly disease that affects millions worldwide. This study explores the potential of combining ruxolitinib, a drug that targets the immune system, with artemether-lumefantrine, a conventional antimalarial drug. The researchers used a [phase 1 clinical trial] to investigate the safety and efficacy of this combination in healthy volunteers. They found that the combination was well-tolerated and had a favorable pharmacokinetic profile, suggesting that it could be a promising treatment for malaria.

A New Strategy for Combating Malaria

This phase 1 clinical trial provides preliminary evidence for the potential of combining ruxolitinib with artemether-lumefantrine as a treatment for malaria. The study found that the combination was well-tolerated and had a favorable pharmacokinetic profile, indicating that it could be a promising new strategy for combating this deadly disease.

Combating the Desert Heatwave

The study highlights the potential of ruxolitinib, a drug that targets the immune system, in combination with artemether-lumefantrine, a conventional antimalarial drug, to combat malaria. The findings offer hope for new treatment strategies that could help reduce the burden of this debilitating disease, which affects millions worldwide.

Dr.Camel's Conclusion

This study provides promising evidence for the potential of combining ruxolitinib with artemether-lumefantrine as a treatment for malaria. The findings suggest that this combination could be a valuable tool in the fight against this deadly disease.

Date :
  1. Date Completed 2022-03-22
  2. Date Revised 2022-03-22
Further Info :

Pubmed ID

34694880

DOI: Digital Object Identifier

PMC8765294

Related Literature

Article Analysis
・Effects of artemether and lumefantrine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.